

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
October 04, 2006

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **September 29, 2006**

**Keryx Biopharmaceuticals, Inc.**  
(Exact Name of Registrant as Specified in Charter)

|   |                             |                                   |
|---|-----------------------------|-----------------------------------|
| <b>Delaware</b>                                   | <b>000-30929</b>            | <b>13-4087132</b>                 |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission File<br>Number) | (IRS Employer Identification No.) |

**750 Lexington Avenue**  
**New York, New York 10022**  
(Address of Principal Executive Offices)

**(212) 531-5965**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- £ Written communications pursuant to Rule 425 under the Securities Act.
  - £ Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - £ Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - £ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
- 
-

**Item 8.01. Other Events.**

On October 4, 2006, Keryx Biopharmaceuticals, Inc. (“Keryx”) issued a press release announcing that Keryx entered into an exclusive licensing agreement (the "Agreement") with Kyowa Hakko Kogyo Co., Ltd. (“Kyowa”), a Tokyo-based company, for the worldwide development and commercialization rights (excluding Japan) to UCN-01, a novel multi-kinase inhibitor for the treatment of cancer that has demonstrated a synergistic effect with agents inhibiting the PI3K pathway, including perifosine. In accordance with the Agreement, Keryx has the right to make, use, sell, distribute, and sublicense UCN-01. In exchange for this license, Keryx will make upfront payments to Kyowa, as well as make payments upon the achievement of certain milestones. Keryx will also pay Kyowa a royalty based on product sales, if any. A copy of such press release is being filed as Exhibit 99.1 to this report and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

The following exhibit is filed as a part of this report:

| <b><u>Exhibit<br/>Number</u></b> | <b><u>Description</u></b>            |
|----------------------------------|--------------------------------------|
| 99.1                             | Press Release dated October 4, 2006. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: October 4, 2006

By: /s/ Ronald C. Renaud, Jr.

---

Ronald C. Renaud, Jr.  
Senior Vice President, Chief Financial Officer,  
Secretary and Treasurer

---

**INDEX TO EXHIBITS**

**Exhibit  
Number**

**Description**

99.1

Press Release dated October 4, 2006.

---